Literature DB >> 241533

The relationship of plasma guanethidine levels to adrenergic blockade.

I E Walter, J Khandelwal, F Falkner, A S Nies.   

Abstract

Seventeen hypertensive patients receiving guanethidine for therapy were studied to determine the relationship of guanethidine plasma levels to adrenergic blockade. Plasma levels of guanethidine were measured by gas chromatography-mass spectrometry, and adrenergic blockade was defined by determining the venous reflex response to Valsalva maneuver or deep breath. A significant correlation was found between the change in the venous reflex response and the fall in mean standing pressure when guanethidine is given to patients maintained on a sodium restricted diet. A linear relationship was found between dose and plasma guanethidine concentration (p less than 0.0001), but there was a 6-fold interindividual variation in the plasma levels resulting from any given dose. Adrenergic blockade occurred when plasma levels were 8 ng/ml or higher. These results indicate that the large individual variation in dose requirements for the hypotensive effects of guanethidine most likely is not due to requirements for greatly different plasma levels of the drug; that the variation must result from pharmacokinetic determinants of differing plasma levels between individuals or from other factors, such as increased plasma volume, which maintain elevated arterial pressure in the face of adrenergic blockade.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 241533     DOI: 10.1002/cpt1975185part1571

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

1.  The effect of a single oral dose of prazosin on venous reflex response, blood pressure and pulse rate in normal volunteers.

Authors:  G J Schapel; W H Betts
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

2.  Alfuzosin and the venous reflex response: studies in normal subjects.

Authors:  A J Sinclair; I B Davies; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.